Bessemer Group Inc. Boosts Position in LeMaitre Vascular, Inc. $LMAT

Bessemer Group Inc. raised its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 292.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 171,838 shares of the medical instruments supplier’s stock after buying an additional 128,033 shares during the period. Bessemer Group Inc. owned about 0.75% of LeMaitre Vascular worth $18,759,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Illinois Municipal Retirement Fund raised its stake in shares of LeMaitre Vascular by 1.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock valued at $906,000 after acquiring an additional 123 shares during the period. NewEdge Advisors LLC boosted its position in LeMaitre Vascular by 4.6% during the 4th quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after purchasing an additional 139 shares during the period. State of Alaska Department of Revenue boosted its position in LeMaitre Vascular by 1.2% during the 4th quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock worth $971,000 after purchasing an additional 147 shares during the period. Federated Hermes Inc. increased its holdings in LeMaitre Vascular by 0.4% in the 2nd quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after purchasing an additional 155 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its position in LeMaitre Vascular by 5.5% in the first quarter. Pictet Asset Management Holding SA now owns 3,259 shares of the medical instruments supplier’s stock valued at $356,000 after purchasing an additional 169 shares during the period. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

LeMaitre Vascular Price Performance

LMAT stock opened at $101.63 on Friday. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. LeMaitre Vascular, Inc. has a 52-week low of $79.00 and a 52-week high of $118.01. The stock’s 50 day moving average is $97.00 and its two-hundred day moving average is $98.42. The company has a market capitalization of $2.32 billion, a PE ratio of 37.50, a P/E/G ratio of 2.82 and a beta of 0.52.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. During the same period in the prior year, the business posted $0.48 EPS. The business’s revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Analysts predict that LeMaitre Vascular, Inc. will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st were paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio is 36.90%.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $111.10, for a total value of $560,388.40. Following the sale, the director owned 3,942 shares in the company, valued at approximately $437,956.20. This represents a 56.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 27,881 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the transaction, the chief executive officer directly owned 1,430,019 shares in the company, valued at $155,428,765.11. The trade was a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 54,453 shares of company stock worth $5,906,174 in the last ninety days. 7.40% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages have commented on LMAT. Zacks Research cut LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Citizens Jmp increased their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Wells Fargo & Company raised their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Freedom Capital raised LeMaitre Vascular to a “hold” rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings cut LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $112.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.